Recent findings have revealed that individuals with certain genetic variations linked to appetite regulation and digestion may experience greater weight loss when using obesity medications like Wegovy and Mounjaro. These insights, published in the esteemed journal *Nature*, could explain disparities in weight loss outcomes and side effects, such as nausea and vomiting, experienced by users.
Genetic Insights into Weight Loss
The study, which analysed data from around 15,000 participants who had previously undergone genetic testing through 23andMe, demonstrated a notable correlation between specific genetic markers and the effectiveness of weight-loss drugs. On average, participants lost 11.7% of their body weight over an eight-month treatment period, with some individuals shedding as much as 30%.
According to Professor Ruth Loos from the University of Copenhagen, one genetic variant was associated not only with increased weight loss but also with a heightened risk of experiencing nausea. “Individuals carrying this variant lost an additional 0.76 kg (approximately 1.6 lbs) on average. Those with two copies of the gene could potentially double this amount,” she explained.
The research highlighted that this genetic variant is more prevalent among individuals of European descent, with 64% carrying at least one copy compared to just 7% of African Americans. This variance suggests that genetics can play a role in determining not just the efficacy of the medication, but also the side effects that may occur during treatment.
Understanding Medication Mechanisms
Wegovy and Mounjaro function by mimicking a natural hormone in the gut that promotes feelings of fullness, effectively curbing appetite. While genetic predispositions can influence outcomes, experts caution that other factors such as age, sex, and geographical background also play a crucial role.
It is estimated that around 1.6 million people in the UK sought out weight-loss medications last year, predominantly through online pharmacies, as access through the NHS remains limited to specific cases of obesity and related health conditions.
In clinical trials, medications like semaglutide (Ozempic and Wegovy) reported an average weight loss of 14%, while tirzepatide (Mounjaro) showed a 20% reduction. The variability in weight loss among users, however, underscores the complexity of obesity treatment.
Broader Influences on Weight Loss Outcomes
Although genetic factors do have an impact, Dr Marie Spreckley from the University of Cambridge emphasised that they represent just one piece of a much larger puzzle. “Behavioural, clinical, and treatment-related factors are the primary drivers of weight loss outcomes,” she noted. Daily exercise, dietary habits, and the level of support available to individuals also significantly affect the success of these medications.
Previous studies indicate that women are more than twice as likely to achieve a 15% weight loss on Mounjaro compared to men. Additionally, demographic factors such as race and age appear to correlate with weight loss efficiency, though the precise reasons remain unclear.
The dosage and duration of medication use are also critical variables that can influence results, highlighting the need for a tailored approach to obesity treatment.
The Future of Weight Management
The prospect of integrating genetic information into treatment plans for obesity could pave the way for “precision medicine,” allowing clinicians to select the most appropriate weight-loss drug based on individual genetic profiles. However, experts like Professor Naveed Sattar from the University of Glasgow caution that while these findings are intriguing, they are not yet ready to revolutionise clinical practice.
“There is a pressing need for more rigorous trial data to better assess the balance of benefits and risks associated with these emerging therapies,” he stated, underscoring the importance of continued research in this area.
Why it Matters
The implications of this research extend beyond individual weight loss; they highlight the intricate interplay between genetics, behaviour, and treatment in addressing obesity. As the prevalence of obesity continues to rise, understanding these factors is crucial for developing effective interventions and personalised treatment plans. This knowledge not only empowers individuals in their weight loss journeys but also informs public health strategies aimed at combating a growing global health crisis.
